Just how big is the bio­phar­ma deal­mak­ing world? In 2019 we saw mega­bil­lions in cash change hands, and that's just the tip of the ice­berg

Back on New Year’s day at the be­gin­ning of 2019, two Chi­nese biotechs called HJB and Mab­Space Bio­sciences merged in­to one out­fit aim­ing to con­quer the world with an an­ti­body plat­form they said could cre­ate new drugs for a range of dis­eases.

You prob­a­bly nev­er heard of it, but their merg­er deal was the open­ing shot for a 365-day burst of deal­mak­ing around the biotech world. At a time un­prece­dent­ed sums are be­ing in­vest­ed in de­vel­op­ing drugs around the world, the match­mak­ing that goes on be­tween a mul­ti­tude of play­ers from Boston to Paris and Lon­don to Shang­hai has reached a fever pitch.

Chris Doko­ma­ji­lar at Deal­For­ma has made a ca­reer out of piec­ing to­geth­er a com­plete mo­sa­ic of every­thing vis­i­ble in the pub­lic do­main. And it’s ex­ten­sive.

In 2019 Doko­ma­ji­lar plumbed a mul­ti­tude of sources to track 2,303 deals — li­cens­ing pacts, op­tions, buy­outs, merg­ers, R&D al­liances, you name it. Most sur­faced briefly with­out any num­bers at­tached to the bliz­zard of re­leas­es they in­spired. One, Bris­tol-My­ers’ $74 bil­lion Cel­gene buy­out, re­shaped the top 20 list of M&A deals over the last decade.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER